Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity

Gitanjali Srivastava; Claudia K. Fox; Aaron S. Kelly; Ania M. Jastreboff; Allen F. Browne; Nancy T. Browne; Janey S.A. Pratt; Christopher Bolling; Marc P. Michalsky; Stephen Cook; Carine M. Lenders; Caroline M. Apovian

doi:10.1002/oby.22385

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity

Gitanjali Srivastava, Claudia K. Fox, Aaron S. Kelly, Ania M. Jastreboff, Allen F. Browne, Nancy T. Browne, Janey S.A. Pratt, Christopher Bolling, Marc P. Michalsky, Stephen Cook, Carine M. Lenders, Caroline M. Apovian

Research output: Contribution to journal › Review article › peer-review

26 Scopus citations

Abstract

A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity-related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization. Current pediatric obesity treatment algorithms for pediatric primary care providers focus primarily on intensive lifestyle intervention with escalation of treatment intensity through four stages of intervention. Although a recent surge in the number of Food and Drug Administration-approved medications for obesity treatment has emerged in adults, pharmacotherapy options for youth remain limited. Recognizing treatment and knowledge gaps related to pharmacological agents and the urgent need for more effective treatment strategies in this population, discussed here are the efficacy, safety, and clinical application of obesity pharmacotherapy in youth with obesity based on current literature. Legal ramifications, informed consent regulations, and appropriate off-label use of these medications in pediatrics are included, focusing on prescribing practices and prescriber limits.

Original language	English (US)
Pages (from-to)	190-204
Number of pages	15
Journal	Obesity
Volume	27
Issue number	2
DOIs	https://doi.org/10.1002/oby.22385
State	Published - Feb 1 2019

Bibliographical note

Funding Information:
Funding agencies: This work was funded with NIH core support from P30DK046200 and P30DK040561. Disclosure: GS has served as a consultant for Johnson and Johnson. CKF receives research support from Novo Nordisk. ASK receives research support (drug/placebo) from Astra Zeneca Pharmaceuticals and serves as a consultant for Novo Nordisk, Orexigen, and Vivus Pharmaceuticals but does not accept personal or professional income for these activities. AMJ has served as a consultant for Novo Nordisk and Medtronic. SC serves as a consultant for Novo Nordisk and Rhythm Pharmaceuticals and has received grant funding from PCORI. CML receives support from New Balance Foundation. CMA reports grants from Aspire Bariatrics, Myos, the Vela Foundation, the Dr. Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, and PCORI; grants and personal fees from Orexigen, GI Dynamics, and Takeda; personal fees from Nutrisystem, Zafgen, Sanofi-Aventis, Novo Nordisk, Scientific Intake, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, EnteroMedics, and Bariatrix Nutrition; and other support from Science-Smart LLC, outside the submitted work. AFB, NTB, JSAP, CB, and MPM, declared no conflict of interest. Author contributions: All authors contributed to the manuscript content. GS conceptualized, wrote the first draft of, and edited the manuscript. All authors reviewed and edited the manuscript for critical content and manuscript preparation. Additional Supporting Information may be found in the online version of this article. Received: 12 April 2018; Accepted: 7 November 2018; Published online 24 January 2019. doi:10.1002/oby.22385

Access

10.1002/oby.22385

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449849

Fingerprint Dive into the research topics of 'Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity'. Together they form a unique fingerprint.

Cite this

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. / Srivastava, Gitanjali; Fox, Claudia K.; Kelly, Aaron S.; Jastreboff, Ania M.; Browne, Allen F.; Browne, Nancy T.; Pratt, Janey S.A.; Bolling, Christopher; Michalsky, Marc P.; Cook, Stephen; Lenders, Carine M.; Apovian, Caroline M.

In: Obesity, Vol. 27, No. 2, 01.02.2019, p. 190-204.

Research output: Contribution to journal › Review article › peer-review

Srivastava, Gitanjali ; Fox, Claudia K. ; Kelly, Aaron S. ; Jastreboff, Ania M. ; Browne, Allen F. ; Browne, Nancy T. ; Pratt, Janey S.A. ; Bolling, Christopher ; Michalsky, Marc P. ; Cook, Stephen ; Lenders, Carine M. ; Apovian, Caroline M. / Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity. In: Obesity. 2019 ; Vol. 27, No. 2. pp. 190-204.

@article{e652047c4bb24b5b9adede1852b77288,

title = "Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity",

abstract = "A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity-related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization. Current pediatric obesity treatment algorithms for pediatric primary care providers focus primarily on intensive lifestyle intervention with escalation of treatment intensity through four stages of intervention. Although a recent surge in the number of Food and Drug Administration-approved medications for obesity treatment has emerged in adults, pharmacotherapy options for youth remain limited. Recognizing treatment and knowledge gaps related to pharmacological agents and the urgent need for more effective treatment strategies in this population, discussed here are the efficacy, safety, and clinical application of obesity pharmacotherapy in youth with obesity based on current literature. Legal ramifications, informed consent regulations, and appropriate off-label use of these medications in pediatrics are included, focusing on prescribing practices and prescriber limits.",

author = "Gitanjali Srivastava and Fox, {Claudia K.} and Kelly, {Aaron S.} and Jastreboff, {Ania M.} and Browne, {Allen F.} and Browne, {Nancy T.} and Pratt, {Janey S.A.} and Christopher Bolling and Michalsky, {Marc P.} and Stephen Cook and Lenders, {Carine M.} and Apovian, {Caroline M.}",

note = "Funding Information: Funding agencies: This work was funded with NIH core support from P30DK046200 and P30DK040561. Disclosure: GS has served as a consultant for Johnson and Johnson. CKF receives research support from Novo Nordisk. ASK receives research support (drug/placebo) from Astra Zeneca Pharmaceuticals and serves as a consultant for Novo Nordisk, Orexigen, and Vivus Pharmaceuticals but does not accept personal or professional income for these activities. AMJ has served as a consultant for Novo Nordisk and Medtronic. SC serves as a consultant for Novo Nordisk and Rhythm Pharmaceuticals and has received grant funding from PCORI. CML receives support from New Balance Foundation. CMA reports grants from Aspire Bariatrics, Myos, the Vela Foundation, the Dr. Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, and PCORI; grants and personal fees from Orexigen, GI Dynamics, and Takeda; personal fees from Nutrisystem, Zafgen, Sanofi-Aventis, Novo Nordisk, Scientific Intake, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, EnteroMedics, and Bariatrix Nutrition; and other support from Science-Smart LLC, outside the submitted work. AFB, NTB, JSAP, CB, and MPM, declared no conflict of interest. Author contributions: All authors contributed to the manuscript content. GS conceptualized, wrote the first draft of, and edited the manuscript. All authors reviewed and edited the manuscript for critical content and manuscript preparation. Additional Supporting Information may be found in the online version of this article. Received: 12 April 2018; Accepted: 7 November 2018; Published online 24 January 2019. doi:10.1002/oby.22385",

year = "2019",

month = feb,

day = "1",

doi = "10.1002/oby.22385",

language = "English (US)",

volume = "27",

pages = "190--204",

journal = "Obesity",

issn = "1930-7381",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity

AU - Srivastava, Gitanjali

AU - Fox, Claudia K.

AU - Kelly, Aaron S.

AU - Jastreboff, Ania M.

AU - Browne, Allen F.

AU - Browne, Nancy T.

AU - Pratt, Janey S.A.

AU - Bolling, Christopher

AU - Michalsky, Marc P.

AU - Cook, Stephen

AU - Lenders, Carine M.

AU - Apovian, Caroline M.

N1 - Funding Information: Funding agencies: This work was funded with NIH core support from P30DK046200 and P30DK040561. Disclosure: GS has served as a consultant for Johnson and Johnson. CKF receives research support from Novo Nordisk. ASK receives research support (drug/placebo) from Astra Zeneca Pharmaceuticals and serves as a consultant for Novo Nordisk, Orexigen, and Vivus Pharmaceuticals but does not accept personal or professional income for these activities. AMJ has served as a consultant for Novo Nordisk and Medtronic. SC serves as a consultant for Novo Nordisk and Rhythm Pharmaceuticals and has received grant funding from PCORI. CML receives support from New Balance Foundation. CMA reports grants from Aspire Bariatrics, Myos, the Vela Foundation, the Dr. Robert C. and Veronica Atkins Foundation, Coherence Lab, Energesis, and PCORI; grants and personal fees from Orexigen, GI Dynamics, and Takeda; personal fees from Nutrisystem, Zafgen, Sanofi-Aventis, Novo Nordisk, Scientific Intake, Xeno Biosciences, Rhythm Pharmaceuticals, Eisai, EnteroMedics, and Bariatrix Nutrition; and other support from Science-Smart LLC, outside the submitted work. AFB, NTB, JSAP, CB, and MPM, declared no conflict of interest. Author contributions: All authors contributed to the manuscript content. GS conceptualized, wrote the first draft of, and edited the manuscript. All authors reviewed and edited the manuscript for critical content and manuscript preparation. Additional Supporting Information may be found in the online version of this article. Received: 12 April 2018; Accepted: 7 November 2018; Published online 24 January 2019. doi:10.1002/oby.22385

PY - 2019/2/1

Y1 - 2019/2/1

N2 - A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity-related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization. Current pediatric obesity treatment algorithms for pediatric primary care providers focus primarily on intensive lifestyle intervention with escalation of treatment intensity through four stages of intervention. Although a recent surge in the number of Food and Drug Administration-approved medications for obesity treatment has emerged in adults, pharmacotherapy options for youth remain limited. Recognizing treatment and knowledge gaps related to pharmacological agents and the urgent need for more effective treatment strategies in this population, discussed here are the efficacy, safety, and clinical application of obesity pharmacotherapy in youth with obesity based on current literature. Legal ramifications, informed consent regulations, and appropriate off-label use of these medications in pediatrics are included, focusing on prescribing practices and prescriber limits.

AB - A growing number of youth suffer from obesity and in particular severe obesity for which intensive lifestyle intervention does not adequately reduce excess adiposity. A treatment gap exists wherein effective treatment options for an adolescent with severe obesity include intensive lifestyle modification or metabolic and bariatric surgery while the application of obesity pharmacotherapy remains largely underutilized. These youth often present with numerous obesity-related comorbid diseases, including hypertension, dyslipidemia, prediabetes/type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, musculoskeletal problems, and psychosocial issues such as depression, anxiety, and social stigmatization. Current pediatric obesity treatment algorithms for pediatric primary care providers focus primarily on intensive lifestyle intervention with escalation of treatment intensity through four stages of intervention. Although a recent surge in the number of Food and Drug Administration-approved medications for obesity treatment has emerged in adults, pharmacotherapy options for youth remain limited. Recognizing treatment and knowledge gaps related to pharmacological agents and the urgent need for more effective treatment strategies in this population, discussed here are the efficacy, safety, and clinical application of obesity pharmacotherapy in youth with obesity based on current literature. Legal ramifications, informed consent regulations, and appropriate off-label use of these medications in pediatrics are included, focusing on prescribing practices and prescriber limits.

UR - http://www.scopus.com/inward/record.url?scp=85060540394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060540394&partnerID=8YFLogxK

U2 - 10.1002/oby.22385

DO - 10.1002/oby.22385

M3 - Review article

C2 - 30677262

AN - SCOPUS:85060540394

VL - 27

SP - 190

EP - 204

JO - Obesity

JF - Obesity

SN - 1930-7381

IS - 2

ER -

Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity

Abstract

Bibliographical note

Access

Other files and links

Cite this